Hallmarks of senescence and aging

被引:234
作者
Dodig, Slavica [1 ]
Cepelak, Ivana [1 ]
Pavic, Ivan [2 ,3 ]
机构
[1] Univ Zagreb, Fac Pharm & Biochem, Dept Med Biochem & Hematol, Zagreb, Croatia
[2] Childrens Hosp Zagreb, Dept Pulmonol Allergol & Immunol, Zagreb, Croatia
[3] Univ Zagreb, Sch Med, Zagreb, Croatia
关键词
senescence; aging; biomarkers; hallmarks; AGE-RELATED DISEASE; REGULATORY T-CELLS; CELLULAR SENESCENCE; TELOMERE LENGTH; SECRETORY PHENOTYPE; OXIDATIVE STRESS; BIOMARKER; IMMUNOSENESCENCE; HETEROGENEITY; INFLAMMATION;
D O I
10.11613/BM.2019.030501
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The complex process of biological aging, as an intrinsic feature of living beings, is the result of genetic and, to a greater extent, environmental factors and time. For many of the changes taking place in the body during aging, three factors are important: inflammation, immune aging and senescence (cellular aging, biological aging). Senescence is an irreversible form of long-term cell-cycle arrest, caused by excessive intracellular or extracellular stress or damage. The purpose of this cell-cycles arrest is to limit the proliferation of damaged cells, to eliminate accumulated harmful factors and to disable potential malignant cell transformation. As the biological age does not have to be in accordance with the chronological age, it is important to find specific hallmarks and biomarkers that could objectively determine the rate of age of a person. These biomarkers might be a valuable measure of physiological, i.e. biological age. Biomarkers should meet several criteria. For example, they have to predict the rate of aging, monitor a basic process that underlies the aging process, be able to be tested repeatedly without harming the person. In addition, biomarkers have to be indicators of biological processes, pathogenic processes or pharmacological responses to therapeutic intervention. It is considered that the telomere length is the weak biomarker (with poor predictive accuracy), and there is currently no reliable biomarker that meets all the necessary criteria.
引用
收藏
页数:15
相关论文
共 88 条
[1]  
[Anonymous], 2001, WHO International Programme on Chemical Safety Biomarkers in Risk Assessment: Validity and Validation
[2]   Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians [J].
Arai, Yasumichi ;
Martin-Ruiz, Carmen M. ;
Takayama, Michiyo ;
Abe, Yukiko ;
Takebayashi, Toru ;
Koyasu, Shigeo ;
Suematsu, Makoto ;
Hirose, Nobuyoshi ;
von Zglinicki, Thomas .
EBIOMEDICINE, 2015, 2 (10) :1549-1558
[3]  
Aspinall R, 2003, AGING ORGANS SYSTEMS, P29, DOI [10.1007/978-94-017-0673-5, DOI 10.1007/978-94-017-0673-5]
[4]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[5]   Immunosenescence: emerging challenges for an ageing population [J].
Aw, Danielle ;
Silva, Alberto B. ;
Palmer, Donald B. .
IMMUNOLOGY, 2007, 120 (04) :435-446
[6]   Mechanisms of development of multimorbidity in the elderly [J].
Barnes, Peter J. .
EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (03) :790-806
[7]   Markers of cellular senescence. Telomere shortening as a marker of cellular senescence [J].
Bernadotte, Alexandra ;
Mikhelson, Victor M. ;
Spivak, Irina M. .
AGING-US, 2016, 8 (01) :3-11
[8]   Telomeres: Implications for Cancer Development [J].
Bernal, Aina ;
Tusell, Laura .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (01)
[9]   Quantitative identification of senescent cells in aging and disease [J].
Biran, Anat ;
Zada, Lior ;
Abou Karam, Paula ;
Vadai, Ezra ;
Roitman, Lior ;
Ovadya, Yossi ;
Porat, Ziv ;
Krizhanovsky, Valery .
AGING CELL, 2017, 16 (04) :661-671
[10]  
Bischoff C, 2005, TWIN RES HUM GENET, V8, P425, DOI 10.1375/183242705774310079